

REMARKS

By this submission, Applicants gratefully acknowledge the allowance of claims 1-3, 5-7, 9, 10, 13, 17, 19, 20, 25, 29-45, 48, and 49. Claims 50 and 51 are new and are supported by page 20, lines 14-32 of the specification. Without prejudice to further prosecution, Applicants have cancelled claims 46-47. Thus, the rejections directed to these claims are obviated.

The Action objects to the "raw sequence listing" because it asserts that the terminal amino acid sequence "Ala-Ala-Cys" was "not present in the amino acid sequences of the original sequence listing presented on February 25, 2002." While it is accurate that the terminal amino acid sequence "Ala-Ala-Cys" was not listed in the first sequence submission, page 14, table 1 of the specification clearly shows that "(beta-A)(beta-A)C" is terminal sequence for all seven listed sequences. "(beta-A)(beta-A)C" is alanine, alanine, cysteine. Thus, the corrected sequence listing properly includes the amino acids found in the table, which is part of the original specification.

The correction in the sequence listing from Homo Sapiens to Borrelia Burgdorferi was a result of an inadvertent data entry error. It is clear from the entire scope of the application that the sequences are derived from a Borrelia Burgdorferi organism. Additionally, previous versions of the sequence listing record the origin of the organism as Borrelia Burgdorferi.

CONCLUSION

Applicants believe the claims are now in condition for allowance. If any additional fee is due, the Commissioner is authorized to charge such fees to Perkins Coie's Deposit Account No. **50-2586**. If anything can be done to further this application, please contact the undersigned at 310-788-9900.

Respectfully submitted,

PERKINS COIE LLP

Dated: January 11, 2005

By: 

Lauren Sliger
Reg. No. 51,086

Cust. No. 34055

Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-1208
Phone: (310) 788-9900
Fax: (310) 788-3399